{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:26:11Z","timestamp":1790738771095,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Melanoma is an aggressive skin cancer derived from melanocyte, which shows high response rate to cancer immunotherapy, such as immune checkpoint inhibitors (ICIs). Vitiligo is an autoimmune skin disease resulting from the destruction of melanocytes by autoreactive CD8<jats:sup>+<\/jats:sup> T cells. Vitiligo induced by cancer immunotherapy is a favorable prognostic factor in patients with melanoma, and growing evidence supports the fact that melanocyte\/melanoma-shared antigen (MSA)-specific CD8<jats:sup>+<\/jats:sup> T cells infiltrated in the tumor (melanoma) and skin (vitiligo) microenvironment play pivotal roles in the prognosis of both diseases. Thus, cellular communications that promote MSA-specific CD8<jats:sup>+<\/jats:sup> T cells recruitment, proliferation, and effector functions are now seen as key targets to enhance the efficacy of current therapies for both diseases. Here, we discussed recent advancements in illustrating immune signaling pathways and immune cell types that regulate migration, proliferation, and function of MSA-specific CD8<jats:sup>+<\/jats:sup> T cells in melanoma and vitiligo; and future immunotherapeutic approaches that may enhance clinical outcomes of both diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2022.866703","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T09:58:00Z","timestamp":1648807080000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Networks of CD8+ T Cell Response Activation in Melanoma and Vitiligo"],"prefix":"10.3389","volume":"13","author":[{"given":"Keitaro","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01464","article-title":"Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade","volume":"38","author":"Betof Warner","year":"2020","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.57.4756","article-title":"Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and its Association With Survival: A Systematic Review and Meta-Analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis During Vitiligo and May Serve as Biomarkers of Disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","article-title":"Suction Blistering the Lesional Skin of Vitiligo Patients Reveals Useful Biomarkers of Disease Activity","volume":"76","author":"Strassner","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-Like Lesions Occurring in Patients Receiving Anti-Programmed Cell Death-1 Therapies are Clinically and Biologically Distinct From Vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.07.058","article-title":"Vitiligo-Like Depigmentation in Patients Receiving Programmed Cell Death-1 Inhibitor Reflects Active Vitiligo","volume":"78","author":"Fukuda","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/ijms18020404","article-title":"Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways","volume":"18","author":"Li","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6622","article-title":"Immunotherapy With a Sting","volume":"369","author":"Gajewski","year":"2020","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18020404","article-title":"Melanoma-Intrinsic \u03b2-Catenin Signalling Prevents Anti-Tumour Immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0085-8","article-title":"A Natural Killer-Dendritic Cell Axis Defines Checkpoint Therapy-Responsive Tumor Microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK Cells Stimulate Recruitment of Cdc1 Into the Tumor Microenvironment Promoting Cancer Immune Control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00143-y","article-title":"Flt3 Ligand Augments Immune Responses to Anti-DEC-205-NY-ESO-1 Vaccine Through Expansion of Dendritic Cell Subsets","volume":"1","author":"Bhardwaj","year":"2020","journal-title":"Nat Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic Cancer Vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200962","article-title":"AIM2 Regulates Anti-Tumor Immunity and is a Viable Therapeutic Target for Melanoma","volume":"218","author":"Fukuda","year":"2021","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.011","article-title":"Vitiligo: Mechanistic Insights Lead to Novel Treatments","volume":"140","author":"Frisoli","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8995","article-title":"scRNA-Seq of Human Vitiligo Reveals Complex Networks of Subclinical Immune Activation and a Role for CCR5 in T(reg) Function","volume":"13","author":"Gellatly","year":"2021","journal-title":"Sci Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30609-7","article-title":"Ruxolitinib Cream for Treatment of Vitiligo: A Randomised, Controlled, Phase 2 Trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and Cellular Insights Into T Cell Exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","article-title":"Adaptive Resistance to Therapeutic PD-1 Blockade is Associated With Upregulation of Alternative Immune Checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the Multicellular Ecosystem of Metastatic Melanoma by Single-Cell RNA-Seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-15-0255","article-title":"Classifying Cancers Based on T-Cell Infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-13-3271","article-title":"Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment With Response to Anti-PD-1 Therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0357-y","article-title":"A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4059","article-title":"Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"Jama"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated With Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15440","article-title":"Acquired Ifn\u03b3 Resistance Impairs Anti-Tumor Immunity and Gives Rise to T-Cell-Resistant Melanoma Lesions","volume":"8","author":"Sucker","year":"2017","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-19-1409","article-title":"Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade","volume":"10","author":"Torrejon","year":"2020","journal-title":"Cancer Discovery"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/2159-8290.Cd-21-04","article-title":"Overcoming PD-1 Blockade Resistance With CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients With Metastatic Melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discovery"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00675","article-title":"Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma","volume":"39","author":"Diab","year":"2021","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14500","article-title":"IFN-\u03b3-Induced PD-L1 Expression on Human Melanocytes is Impaired in Vitiligo","author":"Willemsen","year":"2021","journal-title":"Exp Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/s41598-018-19407-w","article-title":"PD-L1 Reverses Depigmentation in Pmel-1 Vitiligo Mice by Increasing the Abundance of Tregs in the Skin","volume":"8","author":"Miao","year":"2018","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.527","article-title":"Maintenance Therapy of Adult Vitiligo With 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo-Controlled Study","volume":"135","author":"Cavali\u00e9","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aam6346","article-title":"Resident Memory T Cells in the Skin Mediate Durable Immunity to Melanoma","volume":"2","author":"Malik","year":"2017","journal-title":"Sci Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo Skin Is Imprinted With Resident Memory CD8 T Cells Expressing Cxcr3","volume":"138","author":"Boniface","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody Blockade of IL-15 Signaling has the Potential to Durably Reverse Vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci Transl Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a Expression Defines Tissue-Resident CD8(+) T Cells Poised for Cytotoxic Function in Human Skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3962","article-title":"Hair Follicle-Derived IL-7 and IL-15 Mediate Skin-Resident Memory T Cell Homeostasis and Lymphoma","volume":"21","author":"Adachi","year":"2015","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood.v97.1.14","article-title":"Interleukin 15: Biology and Relevance to Human Disease","volume":"97","author":"Fehniger","year":"2001","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.04.027","article-title":"Jak Inhibitors Reverse Vitiligo in Mice But Do Not Deplete Skin Resident Memory T Cells","volume":"141","author":"Azzolino","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.032","article-title":"Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo","volume":"139","author":"Richmond","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16073","article-title":"Enhanced Anti-Tumour Immunity Requires the Interplay Between Resident and Circulating Memory CD8(+) T Cells","volume":"8","author":"Enamorado","year":"2017","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0812-9","article-title":"Tissue-Resident Memory CD8(+) T Cells Promote Melanoma-Immune Equilibrium in Skin","volume":"565","author":"Park","year":"2019","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41467-020-14471-1","article-title":"Bempegaldesleukin Selectively Depletes Intratumoral Tregs and Potentiates T Cell-Mediated Cancer Therapy","volume":"11","author":"Sharma","year":"2020","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.866703\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T09:58:02Z","timestamp":1648807082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.866703\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2022.866703"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.866703","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"article-number":"866703"}}